Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now
01:30pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
The 7 Best Stocks to Buy on a Dip
06:30pm, Tuesday, 29'th Nov 2022
Investors looking for the best stocks to buy on a dip have plenty of options, depending on how they think of the term “dip.” The dip can suggest a market dominator that is trading near its low, or
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases
02:10pm, Friday, 25'th Nov 2022
Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
04:19pm, Tuesday, 22'nd Nov 2022 Benzinga
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.
Aenza S.A.A. (NYSE: AENZ) shares surged 42.7% to $3.
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances
02:46pm, Wednesday, 16'th Nov 2022 Zacks Investment Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
05:56pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
Catalyst Pharmaceuticals: Undervalued And Likely To Outperform
04:42pm, Tuesday, 15'th Nov 2022
Catalyst Pharmaceuticals is in the process of entering new markets for its drug, Firdapse. It's also generating plenty of cash to spend on generating more growth.
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
07:05pm, Monday, 14'th Nov 2022 Zacks Investment Research
Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now
05:45pm, Monday, 14'th Nov 2022 Zacks Investment Research
Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
02:40pm, Monday, 14'th Nov 2022 Zacks Investment Research
Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now
02:17pm, Monday, 14'th Nov 2022
Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
01:30pm, Monday, 14'th Nov 2022 Zacks Investment Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
11:18am, Monday, 14'th Nov 2022
Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
07:13pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
03:48pm, Thursday, 10'th Nov 2022
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
